[{"orgOrder":0,"company":"Akros Pharma","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JTT-861","moa":"Pyruvate dehydrogenase kinase (PDHK)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akros Pharma \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Icon Plc"},{"orgOrder":0,"company":"Corteria Pharmaceuticals","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"COR-1167","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Corteria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corteria Pharmaceuticals \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Corteria Pharmaceuticals \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Cromos Pharma | Data Management 365 | Keystat | R-Pharm | K-Research"},{"orgOrder":0,"company":"Reponex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"Granulocyte colony stimulating factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reponex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Reponex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reponex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XTR004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sinotau Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinotau Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XTR003","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sinotau Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinotau Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"SRW","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"SRW Cel System","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TruDiagnostic \/ SRW","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ SRW"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"L-Nutra | Peak Human Labs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Peak Human Labs Calorie Mimetic Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ L-Nutra | Peak Human Labs","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ L-Nutra | Peak Human Labs"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Inapplicable"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Adventa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Breastmilk","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Adventa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Adventa Biosciences"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Optigenex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"AC-11","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Optigenex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Optigenex, Inc"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TruDiagnostic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Inapplicable"},{"orgOrder":0,"company":"Kunming Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KPCXM18","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kunming Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kunming Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kunming Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ropocamptide","moa":"Hepatitis B virus membrane","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Cutaneous Injection","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dermal","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8601","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AstraZeneca \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Moderna Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"Merck & Co \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Genentech"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"Wake Forest University Health Sciences \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Genentech"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue-type plasminogen activator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"University of Pennsylvania \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Genentech"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AB-1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hemostemix","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ACP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hemostemix \/ Mcgill University Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMG0001","moa":"VEGF-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lomecel-B","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ National Heart, Lung, and Blood Institute | Ann & Robert H Lurie Children's Hospital of Chicago | University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia \/ CellProthera"},{"orgOrder":0,"company":"Seqens","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Seqens \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"Seqens \/ CellProthera"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intraperitoneal Solution","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Argenx","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ IQVIA"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Repulsive guidance molecule A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"University of Birmingham","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Glenzocimab","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acticor Biotech SAS \/ University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ University of Birmingham"},{"orgOrder":0,"company":"Ever Supreme Bio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ever Supreme Bio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ever Supreme Bio Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ever Supreme Bio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Thrombolytic Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Mutant Pro-Urokinase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thrombolytic Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thrombolytic Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Thrombolytic Science \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":1.1100000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1100000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Longview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Longview Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Longview Ventures"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"REGN7508","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"REGN7508","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PL-3994","moa":"Atrial natriuretic peptide receptor A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APD418","moa":"Adrenergic receptor beta-3 (ADRB3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Grand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Grand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sinai Hospital, Canada \/ Sunnybrook Health Sciences Centre | McMaster Children's Hospital | The Rotunda Hospital | John Hunter Hospital | Royal Alexandra Hospital | Centre Hospitalier de l'Universite Laval | Royal North Shore Hospital | Prince of Wales Hospital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Balovaptan","moa":"Vasopressin V1a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Scripps Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metolazone","moa":"Thiazide-sensitive sodium-chloride cotransporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Scripps Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Scripps Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scripps Health \/ Inapplicable"},{"orgOrder":0,"company":"NHS Greater Glasgow and Clyde","sponsor":"University of Glasgow | NuvOx Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dodecafluoropentane","moa":"Blood gas interface","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS Greater Glasgow and Clyde","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NHS Greater Glasgow and Clyde \/ University of Glasgow | NuvOx Pharma"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Lee Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Lee Pharma"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivacelle Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivacelle Bio \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ US Navy"},{"orgOrder":0,"company":"TMS","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"TMS-007","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TMS","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"TMS \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"TMS \/ Biogen"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LT-3001","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Chang Gung University","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Chang Gung University","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Chang Gung University"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Northland Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Gletimbetasin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Northland Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beijing Northland Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Northland Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silver Creek \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Inapplicable"},{"orgOrder":0,"company":"Biocells (Beijing) Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BXOS110","moa":"PSD95","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biocells (Beijing) Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocells (Beijing) Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocells (Beijing) Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Scp776","moa":"IGF-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silver Creek \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Swiss National Science Foundation | Pharming","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University Hospital, Basel \/ Swiss National Science Foundation | Pharming","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Basel \/ Swiss National Science Foundation | Pharming"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Flurpiridaz","moa":"Mitochondrial complex I","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GE Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GE Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HSY244","moa":"Unknown","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Kitasato University","sponsor":"Aetas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"M201-A","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kitasato University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kitasato University \/ Aetas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kitasato University \/ Aetas Pharma"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jakob Stensballe","sponsor":"Cellphire Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jakob Stensballe","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jakob Stensballe \/ Cellphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jakob Stensballe \/ Cellphire Therapeutics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHPL-49","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hutchmed \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC6019-0001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN9933","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cell2Cure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cell2Cure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cell2Cure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cell2Cure \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"The University of Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acticor Biotech SAS \/ The University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ The University of Birmingham"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ INKEF Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ INKEF Capital"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Inapplicable"},{"orgOrder":0,"company":"NoNO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NoNO-42","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NoNO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NoNO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NoNO \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kowa Research Institute, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kowa Research Institute, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kowa Research Institute, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Research Institute, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NST-1024","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"GFA-918","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BIO-CAT \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"BIO-CAT \/ KGK Science"},{"orgOrder":0,"company":"National University of Singapore","sponsor":"A*STAR | AMILI Pte. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ca-Akg","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University of Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"National University of Singapore \/ A*STAR | AMILI Pte. Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"National University of Singapore \/ A*STAR | AMILI Pte. Ltd."},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Endocalyx Pro","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC","highestDevelopmentStatusID":"8","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Dutch Heart Foundation | Dutch Kidney Foundation | Microvascular Health Solutions LLC"},{"orgOrder":0,"company":"Hospital Universitari de Bellvitge","sponsor":"Spanish Society of Nephrology | Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hospital Universitari de Bellvitge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hospital Universitari de Bellvitge \/ Spanish Society of Nephrology | Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Hospital Universitari de Bellvitge \/ Spanish Society of Nephrology | Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PORTUGAL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zamicastat","moa":"Dopamine beta-hydroxylase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Inapplicable"},{"orgOrder":0,"company":"Afimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DS102","moa":"Reperfusion stress","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Afimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pharma 2100","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharma 2100","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharma 2100 \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharma 2100 \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laval University","sponsor":"Canadian Institutes of Health Research | Resverlogix","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laval University \/ Canadian Institutes of Health Research | Resverlogix","highestDevelopmentStatusID":"8","companyTruncated":"Laval University \/ Canadian Institutes of Health Research | Resverlogix"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Temanogrel","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olmesartan Medoxomil","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Arkansas","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cobimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Arkansas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"University of Arkansas \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Arkansas \/ Genentech"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NHS National Waiting Times Centre Board","sponsor":"British Heart Foundation | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS National Waiting Times Centre Board","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cereno Scientific \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Imara","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Imara","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Imara"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Shanghai Zhongshan Hospital","sponsor":"Beijing Continent Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Zhongshan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhongshan Hospital \/ Beijing Continent Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"Apolipoprotein(a) (LPA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johns Hopkins University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Merck & Co"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Phosphodiesterase 4 | Phosphodiesterase 3 | Adenosine receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | Norwegian Health Association | Norwegian Association for Children with Congenital Heart Disease"},{"orgOrder":0,"company":"Bial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"PORTUGAL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zamicastat","moa":"Dopamine beta-hydroxylase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DFV890","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AZD5462","moa":"Relaxin receptor 1 (RXFP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vericiguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Bayer AG"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Fortrea"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CK-4021586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Diao Jiuhong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zhibitai","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Chengdu Diao Jiuhong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chengdu Diao Jiuhong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Diao Jiuhong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zomagen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National Institute for Health Research \/ Manchester University NHS Foundation Trust"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ataciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Rancho Santa Fe Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Rancho Santa Fe Bio"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"Phosphodiesterase 9 (PDE9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.8,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Morgan Stanley"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Afimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Epeleuton","moa":"Reperfusion stress","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Afimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"antiasthmatics\/antiallergics: leukotriene receptor antagonists","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"HRS-5346","moa":"Lipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":1.97,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.97,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck & Co"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ JanOne"},{"orgOrder":0,"company":"JanOne","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"JanOne \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Alliance Global Partners"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ SPYR Technologies"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"||Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARM210","moa":"RYR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ARMGO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"CYP11B2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Enclitide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Qishen Yiqi","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"TP ICAP Midcap","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ TP ICAP Midcap","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ TP ICAP Midcap"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Asundexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Population Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Asundexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Population Health Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Population Health Research Institute"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Asundexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Dongzhimen Hospital, Beijing","sponsor":"The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Buqitongluo","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Dongzhimen Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Dongzhimen Hospital, Beijing \/ The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer","highestDevelopmentStatusID":"8","companyTruncated":"Dongzhimen Hospital, Beijing \/ The Affiliated Hospital of Changchun University of Chinese Medicine | The Affiliated Hospital of Shandong University of Chinese Medicine | The Affiliated Hospital of Chengdu University of Chinese Medicine | The Second Affiliated Hospital of Tianjin Univer"},{"orgOrder":0,"company":"CVI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CVI-LM001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CVI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"CVI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CVI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TSG-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"National University Heart Centre, Singapore","sponsor":"AstraZeneca | University of Otago","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AZD5718","moa":"FLAP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University Heart Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National University Heart Centre, Singapore \/ AstraZeneca | University of Otago","highestDevelopmentStatusID":"8","companyTruncated":"National University Heart Centre, Singapore \/ AstraZeneca | University of Otago"},{"orgOrder":0,"company":"Valo Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OPL-0301","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valo Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OPC 131461","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HSK31679","moa":"THR-?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CRD-4730","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SPC1001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"OPC-131461","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-1893","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FCN-159","moa":"MEK1 \/ MEK2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xuanwu Hospital, Beijing \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"H001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Livzon Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Livzon Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta-2 adrenergic receptor | Adrenergic receptor alpha-1 | Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LTP001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.26000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"LXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NST-1024","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TPN171H","moa":"Phosphodiesterase-5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Shanghai Institute of Materia Medica, Chinese Academy of Sciences"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Jia Shen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSK31679","moa":"THR-?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-1893","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HRS-1893","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ BTIG"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||Tryptophan 5-hydroxylase 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Elixir Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Elixir Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Percutaneous Implant","sponsorNew":"Elixir Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elixir Medical \/ Inapplicable"},{"orgOrder":0,"company":"Novasep","sponsor":"Celladon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"AAV1\/SERCA2a","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novasep","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Percutaneous Injection","sponsorNew":"Novasep \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Novasep \/ Celladon"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"St. Antonius Hospital | Diagram","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ St. Antonius Hospital | Diagram"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AK102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-AGT01","moa":"Angiotensinogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR-2004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Kinevant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"International University of Health and Welfare","sponsor":"Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"International University of Health and Welfare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"International University of Health and Welfare \/ Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"International University of Health and Welfare \/ Japan Agency for Medical Research and Development | Keio University | Chugai Pharmaceutical"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amnio Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kardigan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Tonlamarsen","moa":"STAT3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Kardigan \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kardigan \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"||Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"scPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UT Southwestern Medical Center \/ scPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ scPharmaceuticals"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"Integrin alpha-IIb\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CeleCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"E-Star Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Inapplicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"E-Star Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SHR-1209","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XXB750","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGN7544","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8233","moa":"PCSK9 messenger RNA (PCSK9 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-1893","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QCZ484","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3 messenger RNA (ANGPTL3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Phosphodiesterase 3A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Y-6","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"AgelessRx","sponsor":"University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ University of California, Los Angeles"},{"orgOrder":0,"company":"David J. Gagnon","sponsor":"MaineHealth | National Institute of General Medical Sciences | University of New England","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Bacterial dihydrofolate reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"David J. Gagnon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England","highestDevelopmentStatusID":"8","companyTruncated":"David J. Gagnon \/ MaineHealth | National Institute of General Medical Sciences | University of New England"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MEDI6570","moa":"Lectin-like oxidized LDL receptor (OLR1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ TIMI Study Group"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat","highestDevelopmentStatusID":"8","companyTruncated":"Rigshospitalet \/ Novo Nordisk | Simon Spies Fonden | Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ponsegromab","moa":"monoclonal antibodies: mouse","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Translational Sciences, Inc.","sponsor":"University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Translational Sciences, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona","highestDevelopmentStatusID":"8","companyTruncated":"Translational Sciences, Inc. \/ University of Cincinnati | National Institute of Neurological Disorders and Stroke | Medical University of South Carolina | University of Arizona"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IMC-001","moa":"Programmed cell death 1 ligand 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneOnco \/ ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneOnco \/ ImmuneCare Biopharmaceuticals | The First Affiliated Hospital of Nanyang Medical College"},{"orgOrder":0,"company":"Abcentra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Orticumab","moa":"Oxidized LDL","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Abcentra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abcentra \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abcentra \/ Inapplicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tourmaline Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prothena","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Celixir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"iMP Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celixir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SanBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Inapplicable"},{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ BioCardia"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"SMITH & NEPHEW INC \/ Healiva","highestDevelopmentStatusID":"8","companyTruncated":"SMITH & NEPHEW INC \/ Healiva"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amnio Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Inapplicable"},{"orgOrder":0,"company":"Spaulding Rehabilitation Hospital","sponsor":"BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Spaulding Rehabilitation Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Rehabilitation Hospital \/ BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Spaulding Rehabilitation Hospital \/ BioSensics | MGH Institute of Health Professions | Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"SolasCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SolasCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Inapplicable"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"SolasCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SolasCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Inapplicable"},{"orgOrder":0,"company":"SolasCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SolasCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Inapplicable"},{"orgOrder":0,"company":"Intervene Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Intervene Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intervene Immune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intervene Immune \/ Inapplicable"},{"orgOrder":0,"company":"Korea University Guro Hospital","sponsor":"Dt&Sanomedics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Korea University Guro Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Guro Hospital \/ Dt&Sanomedics","highestDevelopmentStatusID":"8","companyTruncated":"Korea University Guro Hospital \/ Dt&Sanomedics"},{"orgOrder":0,"company":"Palak Shah","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palak Shah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palak Shah \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Palak Shah \/ Abbott Laboratories"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TIMI Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"Angiopoietin like 3 (ANGPTL3) mRNA | Asialoglycoprotein receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ TIMI Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ TIMI Study Group"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Evazarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION904","moa":"Angiotensinogen messenger RNA (AGT mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-APOC3","moa":"ApoC-III messenger RNA (APOC3 mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LY3819469","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"LPA mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ResoTher Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RTP-026","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ResoTher Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ResoTher Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ResoTher Pharma \/ Inapplicable"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Sunnybrook Health Sciences Centre | Mount Sinai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Sunnybrook Health Sciences Centre | Mount Sinai Hospital"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BMS-986259","moa":"RXFP1\/RXFP2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Momentum Research Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Momentum Research Inc","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Momentum Research Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verinurad","moa":"Solute carrier family 22 member 12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ SGS Life Sciences"},{"orgOrder":0,"company":"Yale University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Merck & Co"},{"orgOrder":0,"company":"Mari\u00eblle Scheffer","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mari\u00eblle Scheffer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mari\u00eblle Scheffer \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Mari\u00eblle Scheffer \/ AstraZeneca"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salfaprodil","moa":"NMDA receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Tiantan Hospital \/ Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Zhejiang Apeloa Jiayuan Pharmaceutical | Subei People's Hospital | The First Hospital of Jilin University | First Hospital of China Medical University | General Hospital of Shenyang Military Region | The First Affiliated Hospital of BaoTou Medical College"},{"orgOrder":0,"company":"Stanford University","sponsor":"Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AZD9977","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Calcium channel unspecific (CaC)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Manchester University NHS FT","sponsor":"National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Manchester University NHS FT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","highestDevelopmentStatusID":"8","companyTruncated":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford"},{"orgOrder":0,"company":"Michael Fu","sponsor":"AstraZeneca | G\u00f6teborg University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Michael Fu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Fu \/ AstraZeneca | G\u00f6teborg University","highestDevelopmentStatusID":"8","companyTruncated":"Michael Fu \/ AstraZeneca | G\u00f6teborg University"},{"orgOrder":0,"company":"University of Calgary","sponsor":"University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Cleveland Clinic \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ AstraZeneca"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Amgen Inc"},{"orgOrder":0,"company":"Nanjing Yoko Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Nanjing Yoko Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanjing Yoko Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanjing Yoko Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ARM210","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARMGO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaDiall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimolegin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PharmaDiall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaDiall \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaDiall \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rong Zhang","sponsor":"National Institute on Aging | Texas Health Resources | Michigan State University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rong Zhang","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rong Zhang \/ National Institute on Aging | Texas Health Resources | Michigan State University","highestDevelopmentStatusID":"8","companyTruncated":"Rong Zhang \/ National Institute on Aging | Texas Health Resources | Michigan State University"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Sung-Hwan Kim","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sung-Hwan Kim","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sung-Hwan Kim \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Sung-Hwan Kim \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MYK-224","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ United Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ United Therapeutics"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Elysium Health"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Calcium","moa":"Phosphate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascension Health \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BIIB131","moa":"EPHX2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Tiantan Hospital \/ Neurodawn Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MAS825","moa":"IL-1?","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-986435","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Population Health Research Institute | Canadian Institutes of Health Research | AMO Pharma | Hearts in Rhythm Organization | Canadian SADS"},{"orgOrder":0,"company":"University of Galway","sponsor":"Health Research Board, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Galway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Galway \/ Health Research Board, Ireland","highestDevelopmentStatusID":"8","companyTruncated":"University of Galway \/ Health Research Board, Ireland"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Cardiac sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IKT-001PRO","moa":"ABL\/PDGFR?\/PDGFR?\/c-Kit","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABLi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivacell Biotechnology Espa\u00f1a SLU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etribnabdione","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacell Biotechnology Espa\u00f1a SLU","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivacell Biotechnology Espa\u00f1a SLU \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivacell Biotechnology Espa\u00f1a SLU \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"LPA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Redasemtide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Mayo Clinic | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-Star Biotech \/ Mayo Clinic | PPD","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Mayo Clinic | PPD"},{"orgOrder":0,"company":"Relaxera Pharmazeutische","sponsor":"CBL- Chemical and Biopharmaceutical Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relaxera Pharmazeutische","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LY3540378","moa":"RXFP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KER-012","moa":"ACVR2A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD209","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tissue Engineered Vascular Graft","moa":"Vascular tissue","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Nationwide Children\u2019s Hospital \/ National Heart, Lung, and Blood Institute | Gunze Limited | National Institutes of Health"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"RHEACELL \/ FGK Clinical Research"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NNC0385-0434","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NNC6019-0001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XXB750","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LT3001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Northland Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NL005","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Northland Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Northland Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Northland Biotech \/ Inapplicable"},{"orgOrder":0,"company":"StemCyte","sponsor":"StemCyte","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Umbilical Cord Blood Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCyte \/ StemCyte","highestDevelopmentStatusID":"8","companyTruncated":"StemCyte \/ StemCyte"},{"orgOrder":0,"company":"Bastiaan Driehuys","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hyperpolarized Xenon-129","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bastiaan Driehuys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bastiaan Driehuys \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bastiaan Driehuys \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI765845","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"River 2 Renal Corp.","sponsor":"International HealthCare","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"R2R01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"River 2 Renal Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"River 2 Renal Corp. \/ International HealthCare","highestDevelopmentStatusID":"8","companyTruncated":"River 2 Renal Corp. \/ International HealthCare"},{"orgOrder":0,"company":"NoNO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NoNO-42","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NoNO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"NoNO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NoNO \/ Inapplicable"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Grupo Pedro Ja\u00e9n","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Grupo Pedro Ja\u00e9n","highestDevelopmentStatusID":"8","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Grupo Pedro Ja\u00e9n"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BW-00112","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-1893","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Soluble Corn Fiber","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"Shaanxi Micot Technology Limited Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MT1002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shaanxi Micot Technology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shaanxi Micot Technology Limited Company \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaanxi Micot Technology Limited Company \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Inno Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YN001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Inno Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Inno Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Inno Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RBD4059","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ribocure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribocure Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribocure Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLC7401","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hokkaido University","sponsor":"RAINBOW Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mescenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hokkaido University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hokkaido University \/ RAINBOW Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Hokkaido University \/ RAINBOW Inc."},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RBD5044","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ribocure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribocure Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribocure Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ThromBio Pty. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TBO-309","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ThromBio Pty. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThromBio Pty. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ThromBio Pty. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPC 1001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shin Poong Pharm Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shin Poong Pharm Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"REGN5381","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"APL-9796","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apollo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QCZ484","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Innervate Radiopharmaceuticals","sponsor":"University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"18-F Meta Fluorobenzylguanidine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Innervate Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innervate Radiopharmaceuticals \/ University of Texas System","highestDevelopmentStatusID":"8","companyTruncated":"Innervate Radiopharmaceuticals \/ University of Texas System"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 | Sodium\/potassium-transporting ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Laroprovstat","moa":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"}]

Find Drugs for Cardiology/Vascular Diseases in Phase II Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Protheracytes

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : CellProthera

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Details : ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.

                          Product Name : Protheracytes

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 20, 2025

                          Lead Product(s) : Protheracytes

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : CellProthera

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Seqens Company Banner

                          02

                          Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.

                          Product Name : Mydicar

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : AAV1/SERCA2a

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Celladon

                          Deal Size : $5.4 million

                          Deal Type : Agreement

                          Axplora Novasep

                          03

                          Details : In a post hoc analysis of CABG patients aged 65 years and older treated with 125 units of AGN-151607, a botulinum toxin type A, is a novel investigational neurotoxin the study found a greater risk reduction at 51 percent compared to placebo (nominal p<0....

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 11, 2022

                          Lead Product(s) : Botulinum Toxin A

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          04

                          Lead Product(s) : Ataciguat

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : Rancho Santa Fe Bio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Details : This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countr...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 17, 2021

                          Lead Product(s) : Ataciguat

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Rancho Santa Fe Bio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Sanofi Company Banner

                          05

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 16, 2020

                          Lead Product(s) : Elezanumab

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          06

                          Lead Product(s) : Cerebrolysin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : VASCage GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 11, 2019

                          Lead Product(s) : Cerebrolysin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : VASCage GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Ever Pharma CB

                          07

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 19, 2018

                          Lead Product(s) : AGN-151607

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          08

                          Lead Product(s) : SAR407899

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2017

                          Lead Product(s) : SAR407899

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          10

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 07, 2016

                          Lead Product(s) : Alirocumab

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner